Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma

Show full item record



Permalink

http://hdl.handle.net/10138/318789

Citation

Procopio , G , Bamias , A , Schmidinger , M , Hawkins , R , Rodriguez Sanchez , A , Vazquez Estevez , S , Srihari , N , Kalofonos , H , Bono , P , Pisal , C B , Hirschberg , Y , Dezzani , L , Ahmad , Q , Suarez Rodriguez , C & Jonasch , E 2019 , ' Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma ' , Clinical Genitourinary Cancer , vol. 17 , no. 3 , pp. E526-E533 . https://doi.org/10.1016/j.clgc.2019.01.018

Title: Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma
Author: Procopio, Giuseppe; Bamias, Aristotelis; Schmidinger, Manuela; Hawkins, Robert; Rodriguez Sanchez, Angel; Vazquez Estevez, Sergio; Srihari, Narayanan; Kalofonos, Haralabos; Bono, Petri; Pisal, Chaitali Babanrao; Hirschberg, Yulia; Dezzani, Luca; Ahmad, Qasim; Suarez Rodriguez, Cristina; Jonasch, Eric
Contributor: University of Helsinki, Department of Oncology
Date: 2019-06
Language: eng
Number of pages: 8
Belongs to series: Clinical Genitourinary Cancer
ISSN: 1558-7673
URI: http://hdl.handle.net/10138/318789
Abstract: Patients with intermediate-risk advanced renal cell carcinoma are a heterogeneous population, having either 1 or 2 risk factors. It is unclear whether all patients in this risk category should be treated similarly. A secondary analysis of the PRINCIPAL study of pazopanib found that patients can be stratified by number of risk factors and Eastern Cooperative Oncology Group performance status to more accurately predict outcomes. Introduction: The objective of this study was to determine the effectiveness and safety of pazopanib in patients with intermediate-risk advanced/metastatic renal cell carcinoma in the PRINCIPAL study (NCT01649778). Patients and Methods: Patients had clear-cell advanced/metastatic renal cell carcinoma and met intermediate-risk International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and Memorial Sloan Kettering Cancer Center (MSKCC) criteria. Assessments included progression-free survival, overall survival, objective response rate, and safety. We also evaluated effectiveness based on number of risk factors, age, and performance status (PS), as well as safety in older and younger patients. Results: Three hundred sixty three and 343 intermediate-risk MSKCC and IMDC patients were included, respectively. The median progression-free survival was 13.8 months (95% confidence interval [CI], 10.7-18.1 months) and 7.4 months (95% CI, 6.2-10.3 months) for patients with 1 and 2 MSKCC risk factors, respectively, and 13.1 months (95% CI, 10.7-18.1 months) and 8.1 months (95% CI, 6.4-10.7 months) for patients with 1 and 2 IMDC risk factors, respectively. The median overall survival was not reached and was 15.2 months (95% CI, 12.3-26.5 months) for patients with 1 and 2 MSKCC risk factors, respectively, and 33.9 months (95% CI, 33.9 months to not estimable) and 19.4 months (95% CI, 14.3 months to not estimable) with 1 and 2 IMDC risk factors, respectively. A lower overall response rate was observed with Eastern Cooperative Oncology Group PS >= 2 (vs. PS <2). All-grade treatment-related adverse events occurred in approximately 63% of patients, and the safety profile among older and younger patients was similar. Conclusions: Outcomes with pazopanib in intermediate-risk patients suggest that patients can be further stratified by number of risk factors (1 vs. 2) and Eastern Cooperative Oncology Group PS (<2 vs. >= 2) to more accurately predict outcomes. (C) 2019 Published by Elsevier Inc.
Subject: Intermediate risk
Pazopanib
Prognosis
Renal cell carcinoma
SUNITINIB
THERAPY
3122 Cancers
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S1558767319300448_main_1.pdf 140.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record